Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/1996
12/19/1996WO1996040959A1 Cell line producing analgesic compounds for treating pain
12/19/1996WO1996040922A1 Novel serpin derived from human hypothalamus
12/19/1996WO1996040895A1 Method for identifying alzheimer's disease therapeutics using transgenic animal models
12/19/1996WO1996040885A2 β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION
12/19/1996WO1996040737A1 Reversible cysteine protease inhibitors
12/19/1996WO1996040727A1 Novel nor-pregnanes for inducing hypothalamic effects
12/19/1996WO1996040707A1 Water-soluble adenosine kinase inhibitors
12/19/1996WO1996040706A1 Orally active adenosine kinase inhibitors
12/19/1996WO1996040705A1 C-4' modified adenosine kinase inhibitors
12/19/1996WO1996040687A1 (r)-(z)-1-azabicyclo[2.2.1]heptan-3-one,o-[3-(3-methoxyphenyl)-2-propynyl]oxime maleate as a pharmaceutical agent
12/19/1996WO1996040686A1 Heterocyclic substituted cyclopentane compounds
12/19/1996WO1996040682A1 3-pyridyloxyalkyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
12/19/1996WO1996040651A1 Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
12/19/1996WO1996040650A1 Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
12/19/1996WO1996040649A1 Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
12/19/1996WO1996040647A1 α-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS
12/19/1996WO1996040646A1 Dihydrophthalazine antagonists of excitatory amino acid receptors
12/19/1996WO1996040639A1 Benzenesulfonamide derivatives used as bradykinine antagonists
12/19/1996WO1996040633A1 Small molecule inhibitors of rotamase enzyme activity
12/19/1996WO1996040628A1 Semicarbazones having cns activity and pharmaceutical preparations containing same
12/19/1996WO1996040206A1 Novel kappa receptor selective opioid peptides
12/19/1996WO1996040194A1 Stable formulations of mhc-peptide complexes
12/19/1996WO1996040184A1 New cryptophycins from synthesis
12/19/1996WO1996040143A1 Imidazole compounds
12/19/1996WO1996040140A1 Inhibitors of rotamase enzyme activity
12/19/1996WO1996040139A1 Novel formulations for transdermal delivery of pergolide
12/19/1996WO1996040126A1 1h-4(5)-substituted imidazole derivatives
12/19/1996WO1996040118A1 Thrombin inhibitors
12/19/1996WO1996040116A1 Indolinone compounds for the treatment of disease
12/19/1996WO1996040104A1 Hydroxyl ions as unique therapeutic agents and compounds that modulate ions, compounds
12/19/1996WO1996040100A1 ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THE USE THEREOF AS FACTOR Xa INHIBITORS
12/19/1996WO1996040097A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders
12/19/1996WO1996040085A2 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
12/19/1996WO1996040043A2 Neuroactive steroids of the androstane and pregnane series
12/19/1996WO1996039978A1 Therapeutic use of acetazolamide for the treatment of brain edema
12/19/1996WO1996039834A1 Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
12/19/1996CA2352900A1 Small molecule inhibitors of rotamase enzyme activity
12/19/1996CA2247984A1 Orally active adenosine kinase inhibitors
12/19/1996CA2247983A1 Water-soluble adenosine kinase inhibitors
12/19/1996CA2223996A1 Neuroactive steroids of the androstane and pregnane series
12/19/1996CA2223978A1 Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders
12/19/1996CA2223935A1 Semicarbazones having cns activity and pharmaceutical preparations containing same
12/19/1996CA2223727A1 Arylsulfonylaminobenzene derivatives and the use thereof as factor xa inhibitors
12/19/1996CA2223605A1 Stable formulations of mhc-peptide complexes
12/19/1996CA2223533A1 Imidazole compounds
12/19/1996CA2223500A1 Thrombin inhibitors
12/19/1996CA2223268A1 .alpha.-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
12/19/1996CA2223246A1 Cell line producing analgesic compounds for treating pain
12/19/1996CA2223086A1 Novel serpin derived from human hypothalamus
12/19/1996CA2222972A1 Reversible cysteine protease inhibitors
12/19/1996CA2222690A1 Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
12/19/1996CA2222652A1 1h-4(5)-substituted imidazole derivatives
12/19/1996CA2222316A1 Dihydrophthalazine antagonists of excitatory amino acid receptors
12/19/1996CA2221986A1 Method for identifying alzheimer's disease therapeutics using transgenic animal models
12/19/1996CA2221263A1 Novel formulations for transdermal delivery of pergolide
12/19/1996CA2220642A1 C-4' modified adenosine kinase inhibitors
12/19/1996CA2220076A1 Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
12/19/1996CA2220006A1 Heterocyclic substituted cyclopentane compounds
12/19/1996CA2219755A1 Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
12/19/1996CA2219753A1 (r)-(z)-1-azabicyclo¬2.2.1|heptan-3-one,o-¬3-(3-methoxyphenyl)-2-propynyl|oxime maleate as a pharmaceutical agent
12/19/1996CA2219417A1 Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
12/19/1996CA2196873A1 Therapeutic use of acetazolamide for the treatment of brain edema
12/18/1996EP0748807A1 Derivatives of N-(1,4-diazabicyclo(2.2.2)-oct-2-yl)methyl benzamide, their preparation and their therapeutical use
12/18/1996EP0748792A1 Calcium ketopantothenate with acetylating properties
12/18/1996EP0748628A2 Oral formulations of S(+)-Etodolac
12/18/1996EP0748385A1 Integrative recombinant adenoviruses, preparation thereof and therapeutical uses thereof
12/18/1996EP0748376A1 Rna editing enzyme and methods of use thereof
12/18/1996EP0748320A1 Prodrugs of morpholine tachykinin receptor antagonists
12/18/1996EP0690855B1 Benzopyranes as potassium channel openers
12/18/1996CN1138335A Compounds with growth hormone releasing properties
12/18/1996CN1138334A Compounds with growth hormone releasing properties
12/18/1996CN1138333A New pyridazino |4', g':3.4¨ Pyrrolo-|2,1-a¨ isoquinolines and their use for preparing pharmaceutical compositions
12/18/1996CN1138332A Pyridazino quinoline compounds
12/18/1996CN1138325A Anellated dihydropyridines and their use in the production of pharmaceutical preparations
12/18/1996CN1138324A Anellated dihydropyridines and their use in the production of pharmaceutical preparations
12/18/1996CN1138042A Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
12/18/1996CN1033582C 5H-Benzodiazepine derivatives, pharmaceutical compositions containing same and process for preparing them
12/18/1996CN1033580C N-alkyl-3-phenyl-3-(2-alkylthiophenoxy) propylamines
12/17/1996US5585497 Substituted 1-naphthyl-3-pyrazolecarboxamides which are active on neurotensin
12/17/1996US5585394 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives
12/17/1996US5585388 Substituted pyridines useful as modulators of acetylcholine receptors
12/17/1996US5585378 Can be administered for the prevention and treatment of cognitive dysfunctions
12/17/1996US5585375 Method for alleviating jet lag
12/17/1996US5585374 Anxiolytic agents, antidepressants, cognition activators
12/17/1996US5585372 Tricyclic cefem sulphones
12/17/1996US5585358 Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
12/17/1996US5585351 T-cadherin adhesion molecule
12/17/1996US5585089 Humanized immunoglobulins
12/17/1996CA2111461C 3-aminopiperidine derivatives and related nitrogen containing heterocycles
12/17/1996CA2059526C Partial agonists of the strychnine insensitive glycine modulatory site of the n-methyl-d-asparate receptor complex as neuropsychopharmacological agents
12/14/1996CA2178849A1 N-[(1,4-diazabicyclo[2.2.2]oct-2-yl)methyl]benzamide derivatives, their preparation and their application in therapeutics
12/14/1996CA2178691A1 Oral formulations of s(+)-ibuprofen
12/14/1996CA2178686A1 Oral formulations of s(+)-etodolac
12/12/1996WO1996039509A1 Fibroblast growth factor 15
12/12/1996WO1996039507A1 Fibroblast growth factor 11
12/12/1996WO1996039497A1 Transforming growth factor alpha hi
12/12/1996WO1996039496A1 Use of neuro-derived fetal cell lines for transplantation therapy
12/12/1996WO1996039439A1 Human g-protein receptor hcegh45
12/12/1996WO1996039405A1 Pyridiniminyl-1,2-benzisoxazoles and- benzisothiazoles as antipsychotic agents
12/12/1996WO1996039400A1 Amino-substituted thiadiazoles, pyrimidines, triazines or triazoles useful as ctf receptor antagonists
1 ... 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 ... 1833